AMY-109 is an antibody commercialized by Chugai Pharmaceutical, with a leading Phase II program in Endometriosis. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of AMY-109’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AMY-109 is expected to reach an annual total of $16 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AMY-109 is under development for the treatment of endometriosis and solid tumor. It is administered as a subcutaneous and intravenous injection. The drug candidate is developed based on recycling antibody technology and Biovitals platform. It acts by targeting IL-8 receptor.
Chugai Pharmaceutical Overview
Chugai Pharmaceutical (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, commercialization, manufacturing, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,259,946 million for the fiscal year ended December 2022 (FY2022), an increase of 26% over FY2021. In FY2022, the company’s operating margin was 42.3%, compared to an operating margin of 42.2% in FY2021. In FY2022, the company recorded a net margin of 29.7%, compared to a net margin of 30.3% in FY2021. The company reported revenues of JPY312,240 million for the first quarter ended March 2023, a decrease of 28.8% over the previous quarter.
For a complete picture of AMY-109’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.